Decoy Therapeutics, Inc. (DCOY)
1.23
+0.13
(+11.82%)
USD |
NASDAQ |
Oct 29, 16:00
1.22
-0.01
(-0.81%)
Pre-Market: 09:22
Decoy Therapeutics Enterprise Value : -7.635M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -7.635M |
| October 28, 2026 | -7.704M |
| October 27, 2026 | -7.741M |
| October 26, 2026 | -7.800M |
| October 23, 2026 | -7.773M |
| October 22, 2026 | -7.741M |
| October 21, 2026 | -7.720M |
| October 20, 2026 | -7.685M |
| October 19, 2026 | -7.667M |
| October 16, 2026 | -7.667M |
| October 15, 2026 | -7.635M |
| October 14, 2026 | -7.667M |
| October 13, 2026 | -7.629M |
| October 12, 2026 | -7.528M |
| October 09, 2026 | -7.507M |
| October 08, 2026 | -7.480M |
| October 07, 2026 | -7.433M |
| October 06, 2026 | -7.464M |
| October 05, 2026 | -7.401M |
| October 02, 2026 | -7.348M |
| October 01, 2026 | -7.302M |
| September 30, 2026 | -7.241M |
| September 29, 2026 | -7.156M |
| September 28, 2026 | -7.060M |
| September 25, 2026 | -6.645M |
| Date | Value |
|---|---|
| September 24, 2026 | -6.635M |
| September 23, 2026 | -6.241M |
| September 22, 2026 | -6.640M |
| September 21, 2026 | -6.927M |
| September 18, 2026 | -6.810M |
| September 17, 2026 | -6.784M |
| September 16, 2026 | -6.752M |
| September 15, 2026 | -6.847M |
| September 14, 2026 | -6.847M |
| September 11, 2026 | -6.869M |
| September 10, 2026 | -6.837M |
| September 09, 2026 | -6.821M |
| September 08, 2026 | -6.890M |
| September 04, 2026 | -6.858M |
| September 03, 2026 | -6.757M |
| September 02, 2026 | -6.704M |
| September 01, 2026 | -6.661M |
| August 31, 2026 | -6.666M |
| August 28, 2026 | -6.746M |
| August 27, 2026 | -6.709M |
| August 26, 2026 | -6.688M |
| August 25, 2026 | -6.704M |
| August 24, 2026 | -6.635M |
| August 21, 2026 | -6.587M |
| August 20, 2026 | -6.544M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.691B |
| Alnylam Pharmaceuticals, Inc. | 22.70B |
| Anika Therapeutics, Inc. | 278.45M |
| Savara, Inc. | 874.10M |
| Vericel Corp. | 2.128B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.374M |
| Revenue (Quarterly) | 0.2276M |
| Total Expenses (Quarterly) | 2.601M |
| EPS Diluted (Quarterly) | -4.462 |
| Gross Profit Margin (Quarterly) | 94.02% |
| Profit Margin (Quarterly) | -1.04K% |
| Earnings Yield | -3.84K% |
| Normalized Earnings Yield | -2933.06 |